Research programme: anti-TrkA monoclonal antibodies - Glenmark Pharmaceuticals
Latest Information Update: 04 Nov 2017
At a glance
- Originator Lay Line Genomics
- Developer Glenmark Pharmaceuticals S.A.
- Class Monoclonal antibodies
- Mechanism of Action TrkA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in Switzerland (Parenteral)
- 04 Jun 2014 A lead candidate from this programme has entered clinical development
- 04 Feb 2013 Preclinical trials in Pain in Switzerland (Parenteral)